Skip to main content
ISTH 2023 Main banner
Back

    David-Alexandre TREGOUET, PhD (he/him/his)

    Senior Investigator
    Bordeaux Population Health research center - INSERM UMR1219
    Bordeaux, Aquitaine, France

    Trégouët David-Alexandre, PhD, Molecular Epidemiology of Vascular and Brain Disorders (ELEANOR), Bordeaux Population Health Research Center (France).
    Trained in biostatistics, my research career started with the development of statistical methods to analyze family data as well as genetic polymorphisms in the context of candidate association studies. I then turned to the development/application of statistical tools for the analysis of high-throughput microarray data as part of genome-wide association and expression projects. As former head of the genomics department of the Paris Institute of Cardiometabolism and Nutrition and of the biostatistics/bioinformatics group of the Post-Genomic Platform of the Pitié-Salpêtrière Hospital, I got solid expertise in the generation and analysis of next-generation sequenced data (eg. whole-exome, RNA-sequencing, miRNA-sequencing Chip-Sequencing). I partner with the GENMED Laboratory of Excellence on Medical Genomics to coordinate several genomics projects relying on whole exome/genome sequencing and high-throughput DNA arrays.
    In parallel to these statistical and bioinformatics developments, I am participating in the design and the analysis of several epidemiological studies aiming at identifying susceptibility genes for cardiovascular diseases, my favorite disease being venous thromboembolism (VTE). I am joint coordinator of the French EOVT, FARIVE, MARTHA, MARFAST and PILGRIM studies aimed at identifying genetic factors for VTE. Within the F-CRIN supported INNVOTE network that assembled all French clinician working in the field of VTE, I am responsible of the research programs on VTE genomics. I am co-convener of the International Network of Venous Thrombosis (INVENT) consortium and member of the CHARGE Hemostasis working group. More recently, my interests have turned to epigenetics as novel mechanisms contributing to the inter-individual susceptibility to human diseases with strong emphasis on the latest approaches on DNA methylation, microRNA and proteomic profiling towards the identification of novel molecular biomarkers for thrombosis.

    Presentation(s):